Arrowhead has enrolled 70 patients in a rare cholesterol trial, but can zodasiran clear the Phase 3 bar?
Arrowhead completes Phase 3 YOSEMITE enrollment as zodasiran faces a crucial test of LDL cholesterol lowering in patients with severe HoFH.
Pharma & Biotech
Pharma & Biotech
How Chiesi Global Rare Diseases is positioning lomitapide for earlier lifecycle management in HoFH
CHMP backs paediatric lomitapide for HoFH. Read what this means for clinicians, regulators, and rare disease access across Europe.